SCHEMBL2012858

SCHEMBL2012858

NC(=O)c1cccc2oc3ccccc3c12

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.76
GLA P06280 2/20 0.76
MAOA P21397 3/20 0.47
KDM4E B2RXH2 5/20 0.45
MAPT P10636 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 2/20 0.45
CYP3A4 P08684 1/20 0.45
PGAM1 P18669 1/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45
CDC14B O60729 1/20 0.45
CDC14A Q9UNH5 1/20 0.45
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.44
USP2 O75604 1/20 0.42
CSNK2A2 P19784 1/20 0.42
PTGS1 P23219 1/20 0.42
CSNK2B P67870 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30476189 1.00 ALDH1A1 (0.76) ALDH1A1GLAMAOAKDM4EMAPT
Methanesulfonamide SCHEMBL4789997 0.91 ALDH1A1 (0.64) ALDH1A1GLAMAOAKDM4EMAPT
Methanesulfonamide SCHEMBL4790635 0.89 ALDH1A1 (0.62) ALDH1A1GLAMAOAKDM4EMAPT
SCHEMBL4234802 0.88 ALDH1A1 (0.69) ALDH1A1GLAMAOAKDM4EMAPT
SCHEMBL516363 0.83 ALDH1A1 (0.54) ALDH1A1GLAMAOAKDM4EMAPT
SCHEMBL29685650 0.83 ALDH1A1 (0.54) ALDH1A1GLAMAOAKDM4EMAPT
SCHEMBL4586087 0.81 ALDH1A1 (0.53) ALDH1A1GLAMAOAKDM4EMAPT
SCHEMBL11401526 0.81 ALDH1A1 (0.53) ALDH1A1GLAMAOAKDM4EMAPT
SCHEMBL6238717 0.81 ALDH1A1 (0.53) ALDH1A1GLAMAOAKDM4EMAPT
Silver SCHEMBL11471729 0.80 ALDH1A1 (0.51) ALDH1A1GLAMAOAKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0891354-B1 N-AMINOALKYLDIBENZOFURANCARBOXAMIDES AS DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS NEUROGEN CORP (US) 2001-09-12 EP claimed
EP-3285735-B1 DELIVERY OF SURFACTANT SOLUBLE ANTI-DANDRUFF AGENT PROCTER & GAMBLE (US) 2021-06-23 EP disclosed
EP-3061759-B1 NITRILE SUBSTITUTED DIBENZOFURANS IDEMITSU KOSAN CO (JP) 2019-12-25 EP disclosed
EP-3072943-B1 DIBENZOFURAN/CARBAZOLE-SUBSTITUTED BENZONITRILES IDEMITSU KOSAN CO (JP) 2018-05-02 EP disclosed
CN-105902533-B Purposes of the compound cercosporamide in immunopotentiator is prepared 浙江省医学科学院 2018-04-20 CN disclosed
CN-105902533-B Purposes of the compound cercosporamide in immunopotentiator is prepared 浙江省医学科学院 2018-04-20 CN disclosed
EP-3072943-A1 DIBENZOFURAN/CARBAZOLE-SUBSTITUTED BENZONITRILES Idemitsu Kosan Co., Ltd. (JP) 2016-09-28 EP disclosed
EP-3061759-A1 NITRILE SUBSTITUTED DIBENZOFURANS Idemitsu Kosan Co., Ltd (JP) 2016-08-31 EP disclosed
CN-105902533-A Application of compound cercosporamide in preparation of immunoenhancer 浙江省医学科学院 2016-08-31 CN disclosed
US-20160248026-A1 NITRILE SUBSTITUTED DIBENZOFURANS IDEMITSU KOSAN CO., LTD. (JP) 2016-08-25 US disclosed
US-4935511-A Nervous system, gastrointestinal disorders RORER PHARMACEUTICAL CORPORATION (US) 1990-06-19 US disclosed
WO-1990006113-A1 SUBSTITUTED SATURATED AND UNSATURATED INDOLE QUINOLINE AND BENZAZEPINE CARBOXAMIDES AND THEIR USE AS PHARMACOLOGICAL AGENTS RORER INTERNATIONAL (OVERSEAS) INC. (US) 1990-06-14 WO disclosed
WO-1990006309-A1 HETEROAZABENZOBICYCLIC CARBOXAMIDE 5-HT3, ANTAGONISTS RORER INTERNATIONAL (OVERSEAS) INC. (US) 1990-06-14 WO disclosed
US-4933445-A Heteroazabenzobicyclic carboxamide 5-HT3 antagonists RORER PHARMACEUTICAL CORPORATION (US) 1990-06-12 US disclosed
US-4920219-A Substituted saturated and unsaturated indole quinoline and benzazepine carboxamides and their use as pharmacological agents RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed
US-4920227-A Benzobicyclic carboxamide 5-HT3 antagonists RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed
WO-1989010364-A1 DIBENZOFURANCARBOXAMIDES RORER INTERNATIONAL (OVERSEAS) INC. (US) 1989-11-02 WO disclosed
EP-0339950-A2 Dibenzofurancarboxamides, their use as pharmaceutical agents, a composition containing the same, and a process for the preparation thereof RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1989-11-02 EP disclosed
US-4863921-A Dibenzofurancarboxamides and their pharmaceutical compositions and methods RORER PHARMACEUTICAL CORPORATION (US) 1989-09-05 US disclosed
US-4863921-A Dibenzofurancarboxamides and their pharmaceutical compositions and methods RORER PHARMACEUTICAL CORPORATION (US) 1989-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160248026-A1 NITRILE SUBSTITUTED DIBENZOFURANS DBF4, NXF1, NCF1 ALDH1A1 1679/4885GLA 3390/4885MAOA 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.